VYNE Therapeutics (VYNE) Enterprise Value (QoQ) (2017 - 2026)

VYNE Therapeutics (VYNE) Enterprise Value (QoQ) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 14.07%
Jun 30, 2025 21.14%
Mar 31, 2025 18.28%
Dec 31, 2024 12.35%
Sep 30, 2024 10.14%
Jun 30, 2024 9.13%
Mar 31, 2024 -37.11%
Dec 31, 2023 -115,987.04%
Sep 30, 2023 99.74%
Jun 30, 2023 -30,697.01%
Mar 31, 2023 -146.53%
Dec 31, 2022 100.41%
Sep 30, 2022 17.06%
Jun 30, 2022 15.21%
Mar 31, 2022 -8,246.28%
Dec 31, 2021 98.84%
Sep 30, 2021 -8,545.62%
Jun 30, 2021 99.49%
Mar 31, 2021 -6,251.91%
Dec 31, 2020 97.42%